REMINDER: ORLive Presents: “The Discovery of C’elle(SM): Novel Adult Stem Cell Found in Menstrual Blood”

Virtual Broadcast Center Launches on July 10th at 12 Noon EDT to Present Ground-Breaking Stem Cell Research and Introduce C’elle, the Innovative New Service to Preserve Stem Cells Found in Menstrual Blood

OLDSMAR, FL–(EMWNews – August 7, 2008) – Cryo-Cell International, Inc. (OTCBB: CCEL),

one of the largest and most established family cord blood banks, will

broadcast the discovery of breakthrough EMWNews“>stem cell technology and the

launch of C’elle, the world’s

first service for women to store their own menstrual stem cells for future

use. Produced by OR Live, results will launch on Thursday, July 10th, at 12

noon EDT.

Cryo-Cell’s discovery shows new scientific evidence that menstrual flow,

which results from the shedding of the uterine lining (endometrium) during

menstruation, contains millions of stem cells that have many properties and

characteristics similar to those of both bone marrow and embryonic stem cells.

Through several independent laboratory research studies, these menstrual stem cells have

demonstrated the capability in vitro to differentiate into neural, cardiac,

bone, cartilage, and adipose cells and possibly other cell types. Although

research is preliminary, given their properties, Cryo-Cell believes that these menstrual cells demonstrate compelling promise to

transform regenerative

medicine in coming years.

“Stem cells isolated from menstrual blood are multi-potent, highly prolific

and readily accessible,” said Julie Allickson, PhD, MS, MT (ASCP) Vice

President of Laboratory Operations and Research & Development. “These novel

stem cells demonstrate characteristics of both bone marrow mysenchemal stem

cells and embryonic stem cell markers that may potentially demonstrate

significant promise for future use in clinical regenerative medical

therapies.”

On November 1, 2007, Cryo-Cell announced the introduction of C’elle which

enables women to collect stem cells found in menstrual fluid, which can be

cryogenically preserved in a manner similar to stem cells from umbilical

cord blood and may one day serve as a potential source for promising

regenerative therapies to treat heart disease, diabetes, neurological disorders like

spinal cord injury, Parkinson’s

and Alzheimer’s diseases, in addition to cosmeceutical applications

such as anti-aging therapies.

Preliminary research related to the immunological profile of these unique

menstrual stem cells suggests the that in addition to the donor, these stem

cells may also potentially be used to benefit other family members who are

genetically related to the donor, such as perhaps a parent, sibling or

child.

The virtual broadcast center will include details about the study, the cell

characteristics, information about several preclinical studies currently

under way, and an overview of the C’elle service.

About Cryo-Cell International, Inc.

Based in Oldsmar, Florida, with over 150,000 clients worldwide, Cryo-Cell

is one of the largest and most established family cord blood banks. ISO

9001:2000 certified and accredited by the AABB, Cryo-Cell operates in a

state-of-the-art Good Manufacturing Practice and Good Tissue Practice

(cGMP/cGTP)-compliant facility. Cryo-Cell is a publicly traded company. OTC

Bulletin Board Symbol: CCEL. For more information, please call

1-800-STOR-CELL (1-800-786-7235) or visit www.cryo-cell.com.

Forward-Looking Statement

Statements wherein the terms “believes,” “intends,” “projects” or “expects”

as used are intended to reflect “forward-looking statements” of the

Company. The information contained herein is subject to various risks,

uncertainties and other factors that could cause actual results to differ

materially from the results anticipated in such forward-looking statements

or paragraphs, many of which are outside the control of the Company. These

uncertainties and other factors include the uncertainty of market

acceptance of any potential service offerings relating to types of stem

cells other than cord blood stem cells, including the C’elle service, given

that menstrual stem cells and other new stem cells have not yet been used

in human therapies, and treatment applications using such stem cells are

not likely to be developed and commercialized for many years and are

subject to further research and development; the need for additional

development and testing before determining the ultimate commercial value of

the Company’s intellectual property relating to the menstrual stem cells;

the need to complete certain developments, including completion of clinical

validation and testing, before any new process other than C’elle can be

commercialized, and the Company’s development of its final business and

economic model in offering any such service; any adverse effect or

limitations caused by recent increases in government regulation of stem

cell storage facilities; any increased competition in our business; any

decrease or slowdown in the number of people seeking to store umbilical

cord blood stem cells or decrease in the number of people paying annual

storage fees; any adverse impacts on our revenue or operating margins due

to the costs associated with increased growth in our business, including

the possibility of unanticipated costs relating to the operation of our new

facility; any technological breakthrough or medical breakthrough that would

render the Company’s business of stem cell preservation obsolete; any

material failure or malfunction in our storage facilities; any natural

disaster such as a tornado, other disaster (fire) or act of terrorism that

adversely affects stored specimens; the costs associated with defending or

prosecuting litigation matters and any material adverse result from such

matters; decreases in asset valuations; any continued negative effect from

adverse publicity in the past year regarding the Company’s business

operations; any negative consequences resulting from deriving, shipping and

storing specimens at a second location; and other risks and uncertainties.

The foregoing list is not exhaustive, and the Company disclaims any

obligations to subsequently revise any forward-looking statements to

reflect events or circumstances after the date of such statements. Readers

should carefully review the risk factors described in other documents the

Company files from time to time with the Securities and Exchange

Commission, including the most recent Annual Report on Form 10-KSB,

Quarterly Reports on Form 10-QSB and any Current Reports on Form 8-K filed

by the Company.

To learn more about the study and view a program preview visit OR-Live.

VNR: www.OR-Live.com.

Contact: Alex Fraser Direct of Marketing OR-Live 860 953 2900 x214 [email protected]